[go: up one dir, main page]

DK0626853T3 - Anvendelse af substituerede adeninderivater til behandling af multipel sclerose - Google Patents

Anvendelse af substituerede adeninderivater til behandling af multipel sclerose

Info

Publication number
DK0626853T3
DK0626853T3 DK93906071T DK93906071T DK0626853T3 DK 0626853 T3 DK0626853 T3 DK 0626853T3 DK 93906071 T DK93906071 T DK 93906071T DK 93906071 T DK93906071 T DK 93906071T DK 0626853 T3 DK0626853 T3 DK 0626853T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
treatment
adenine derivatives
substituted adenine
formula
Prior art date
Application number
DK93906071T
Other languages
English (en)
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0626853T3 publication Critical patent/DK0626853T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK93906071T 1992-02-19 1993-02-18 Anvendelse af substituerede adeninderivater til behandling af multipel sclerose DK0626853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0626853T3 true DK0626853T3 (da) 2000-08-07

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93906071T DK0626853T3 (da) 1992-02-19 1993-02-18 Anvendelse af substituerede adeninderivater til behandling af multipel sclerose

Country Status (15)

Country Link
US (4) US5310732A (da)
EP (1) EP0626853B1 (da)
JP (1) JP2688113B2 (da)
AT (1) ATE192045T1 (da)
AU (1) AU682818B2 (da)
BR (1) BR9305907A (da)
CA (1) CA2130275C (da)
CH (1) CH684310A5 (da)
DE (1) DE69328474T2 (da)
DK (1) DK0626853T3 (da)
FI (1) FI943805L (da)
HU (1) HU218656B (da)
NO (2) NO309025B1 (da)
RU (1) RU2130308C1 (da)
WO (1) WO1993016706A1 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
WO1993023058A1 (en) * 1992-05-19 1993-11-25 The Scripps Research Institute Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
CA2191230C (en) * 1994-05-26 2001-02-27 Dennis A. Carson 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996003134A1 (en) * 1994-07-21 1996-02-08 Thomas Jefferson University Treatment of diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
DK0801571T3 (da) * 1994-12-22 2003-01-06 Ortho Pharma Corp Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
SK283821B6 (sk) * 1995-02-10 2004-02-03 Schering Aktiengesellschaft Farmaceutické preparáty na inhibíciu tumornekrózafaktora
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU3851601A (en) * 2000-02-18 2001-08-27 Southern Res Inst Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h- purin-6-amine
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
ATE548376T1 (de) 2000-11-01 2012-03-15 Univ California Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
WO2004028463A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
EP1549141A4 (en) * 2002-09-27 2008-06-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING CLOFARABIN
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
JP5412709B2 (ja) * 2003-03-28 2014-02-12 アレス トレーディング ソシエテ アノニム 改良された経口及び経粘膜デリバリーのためのクラドリビン製剤
EP1608344B1 (en) * 2003-03-28 2010-08-04 Ares Trading S.A. Oral formulations of cladribine
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
CN100471842C (zh) * 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
DK1699459T3 (da) * 2003-12-29 2007-10-08 Can Fite Biopharma Ltd Fremgangsmåde til behandling af multipel sclerose
KR101149242B1 (ko) 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Ｆｃ 영역 변이체
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
CA2590471A1 (en) * 2004-12-22 2006-06-29 Laboratoires Serono S.A. Combination treatment for multiple sclerosis
FI4070800T3 (fi) 2004-12-22 2025-01-14 Merck Serono Sa Kladribiinikuuri multippeliskleroosin hoitoa varten
US8658622B2 (en) 2005-01-14 2014-02-25 Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8845627B2 (en) * 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP2971279B1 (en) 2013-03-15 2019-11-13 The Trustees of Princeton University Methods and devices for high throughput purification
EP3569313A1 (en) 2013-03-15 2019-11-20 GPB Scientific, LLC On-chip microfluidic processing of particles
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
EP3215149A4 (en) 2014-11-06 2018-06-27 Northwestern University Inhibition of cancer cell motility
HK1250543A1 (zh) * 2015-08-24 2018-12-21 日本瑞翁株式会社 用於多步骤细胞纯化和浓缩的方法和装置
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
JP2024508151A (ja) 2021-03-03 2024-02-22 アレス トレーディング ソシエテ アノニム 自己免疫疾患治療のためのｄｍｄを使用する改善された治療法、並びに該治療法を予測及び／又は最適化するためのバイオマーカー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572070C3 (de) * 1966-03-12 1979-03-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Kopiermaterial
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
NZ226672A (en) * 1987-10-30 1991-07-26 Hoffmann La Roche 6-amino-9-(2,3-dideoxy-2-fluoro-b-d-threopentofuranosyl)-9h-purine derivatives and pharmaceutical compositions
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
EP0364559B1 (en) * 1988-03-16 1995-09-20 The Scripps Research Institute Substituted adenine derivatives useful as therapeutic agents
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
JPH07507540A (ja) 1995-08-24
US5310732A (en) 1994-05-10
FI943805A0 (fi) 1994-08-18
CH684310A5 (de) 1994-08-31
HU9402392D0 (en) 1994-10-28
AU3724993A (en) 1993-09-13
FI943805A7 (fi) 1994-10-19
DE69328474T2 (de) 2000-09-28
HU218656B (hu) 2000-10-28
CA2130275C (en) 1999-06-29
NO20000762D0 (no) 2000-02-16
WO1993016706A1 (en) 1993-09-02
NO309025B1 (no) 2000-12-04
US5506213A (en) 1996-04-09
AU682818B2 (en) 1997-10-23
JP2688113B2 (ja) 1997-12-08
CA2130275A1 (en) 1993-09-02
DE69328474D1 (de) 2000-05-31
NO942765D0 (no) 1994-07-25
US5506214A (en) 1996-04-09
EP0626853B1 (en) 2000-04-26
NO942765L (no) 1994-09-13
NO322328B1 (no) 2006-09-18
EP0626853A1 (en) 1994-12-07
ATE192045T1 (de) 2000-05-15
BR9305907A (pt) 1997-10-21
US5541164A (en) 1996-07-30
RU94038043A (ru) 1996-11-20
RU2130308C1 (ru) 1999-05-20
NO20000762L (no) 1994-09-13
HUT68030A (en) 1995-05-29
FI943805L (fi) 1994-10-19

Similar Documents

Publication Publication Date Title
DK0626853T3 (da) Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
DE69333109D1 (de) Therapeutische nukleoside
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
NO990708D0 (no) Bisykliske pyrimidinderivater og deres anvendelse som antikoagulanter
ATE121389T1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
ES2067314T3 (es) 3-benzacepin-zonas sustituidas por un grupo benzociclobutilo o indanil-alquil-amino-alquilo, utiles en el tratamiento de las afecciones cardiovasculares.
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
IT8122675A0 (it) Mercaptoacil derivati di varie proline 4 sostituite e relative composizioni utili per il trattamento dell'ipertensione.
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
IN172468B (da)
FI895447A0 (fi) Substituerade adeninderivat anvaendbara som terapeutiska substanser.
DK0565631T3 (da) Antivirale forbindelser
DE69326474D1 (de) Neue 2-substituierte tricyclische derivate von indan-2-mercaptoacetylamid verwendbar als enkephalinase inhibitoren
DK0710239T3 (da) Nye 9-N-bicycliske nucleosidmidler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
YU4393A (sr) Supstituisani heksahidroazepinoni i tetrahidrobenzazepinoni
DE69418050D1 (de) Antivirale analoge von difluorostaton
DK0512953T3 (da) Fremgangsmåde til fremstilling af benzensulfonamider
SU1410468A1 (ru) 3-цианалкилоксазолидины в качестве альгицида